1. Introduction {#sec1-ijms-20-02866}
===============

In mammals, the molecular processes leading to the production of female gametes are controlled by multiple interactions among different modulators, either hormones or paracrine factors \[[@B1-ijms-20-02866],[@B2-ijms-20-02866]\]. Starting from the observation that exogenous plant-derived cannabinoids, as those present in cannabis extracts like hashish and marijuana, negatively impact fertility \[[@B3-ijms-20-02866],[@B4-ijms-20-02866]\], several reports documented the key-role of the so called "endocannabinoid system" (ECS) on virtually all steps of female reproduction, from fertilization to oviductal transport, embryo implant and development, and pregnancy outcome \[[@B3-ijms-20-02866],[@B5-ijms-20-02866],[@B6-ijms-20-02866],[@B7-ijms-20-02866],[@B8-ijms-20-02866],[@B9-ijms-20-02866]\]. The ECS includes: I) lipid messengers termed "endocannabinoids" (eCBs), such as anandamide (*N*-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG); II) their receptor targets type-1 (CB~1~R) and type-2 (CB~2~R) cannabinoid receptors, G-protein coupled receptor 55 (GPR55), transient receptor potential vanilloid type 1 channel (TRPV1); III) a number of metabolic enzymes among which the eCB-cleaving fatty acid amide hydrolase (FAAH). Moreover, additional "eCB-like" compounds like *N*-palmitoylethanolamine (PEA) and *N*-oleoylethanolamine (OEA), that do not bind to CB~1~R and CB~2~R but can activate GPR55 \[[@B10-ijms-20-02866]\], contribute to modulate eCB signalling.

All major ECS components have been found in female and male reproductive systems \[[@B8-ijms-20-02866],[@B11-ijms-20-02866],[@B12-ijms-20-02866]\], and eCB levels in tissues and body fluids hold promise as disease biomarkers \[[@B12-ijms-20-02866],[@B13-ijms-20-02866]\]. Of note, the presence of a high concentration of AEA in follicular fluid is indicative of mature follicles \[[@B14-ijms-20-02866],[@B15-ijms-20-02866]\], and significant differences of AEA and PEA in serum, and of OEA in follicular fluid, have been recorded between infertile and fertile women \[[@B16-ijms-20-02866]\]. Furthermore, dysregulation of the ECS has been observed in polycystic ovary syndrome (PCOS) onset \[[@B17-ijms-20-02866]\], as well as in altered human endometrial stromal cell decidualization \[[@B18-ijms-20-02866]\].

Assessment of presence and distribution of distinct ECS components in the mammalian ovary seems necessary to clarify their roles in oocyte meiotic maturation and fertilization. In rodent follicles, distinct expression of CB~1~R, CB~2~R, and FAAH supports a different eCB-mediated response in oocyte and in follicle cells \[[@B19-ijms-20-02866]\]. Indeed, CB~1~R is detectable in granulosa cells (GCs) of rat antral follicles, in the ovarian surface epithelium (OSE), and in luteal cells, while CB~2~R and FAAH are localized in oocytes during different stages of ovarian function, as well as in luteal cells \[[@B19-ijms-20-02866]\]. In the human ovary, GCs has a role in the production of endocannabinoids. In fact, the AEA synthetizing enzyme *N*-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) has been detected in GCs of secondary and tertiary follicles but not in oocytes \[[@B20-ijms-20-02866]\]. Conversely, conflicting results have been obtained on CB~1~R and CB~2~R expression. Indeed, El-Talatini and colleagues found both receptors in GCs and oocytes from primordial, primary, and secondary follicles, but not in oocytes derived from antral follicles \[[@B20-ijms-20-02866]\]. Instead, Peralta and colleagues found CB~1~R and CB~2~R in preovulatory oocytes at germinal vesicle (GV), metaphase I (MI), and metaphase II (MII) stages, with a different distribution across the germ cells depending on maturation stage \[[@B21-ijms-20-02866]\]. In human GCs, Agirregoitia and coworkers found that CB~1~R and CB~2~R expression was differentially regulated along oocyte meiotic maturation \[[@B22-ijms-20-02866]\]. Moreover, FAAH and the 2-AG hydrolase monoacylglycerol lipase were also detected in human germ cells during the three stages of meiotic maturation \[[@B23-ijms-20-02866]\]. More recently, López-Cardona and collaborators linked CB~1~R signalling in bovine and mouse oocytes to the activity of two kinases involved in oocyte meiotic maturation, Akt and ERK1/2 \[[@B24-ijms-20-02866],[@B25-ijms-20-02866]\]. Indeed, when oocytes were matured in vitro in the presence of the CB~1~R agonist HU-210, Akt phosphorylation was stimulated, while that of ERK1/2 was inhibited \[[@B24-ijms-20-02866],[@B25-ijms-20-02866]\].

To our knowledge, there is no further information on CB~1~R and CB~2~R expression levels in mammalian oocytes, and nothing at all is known about the presence and action in these cells of the other major eCB-binding receptors GPR55 and TRPV1. Here, we sought to fill this gap by investigating the expression of CB~1~R, CB~2~R, GPR55, and TRPV1, both at mRNA and protein levels, at different stages (GV, MI, and MII) of oocyte meiotic maturation. In addition, since a role for these receptors in the process of meiotic maturation is far from clear, we performed experiments in which oocytes were matured in the presence of specific receptor antagonists to assess kinetics of meiotic maturation, polar body emission, and spindle morphology.

2. Results {#sec2-ijms-20-02866}
==========

2.1. mRNA Levels of eCB-Binding Receptors in GV, MI, and MII Oocytes {#sec2dot1-ijms-20-02866}
--------------------------------------------------------------------

Data obtained from real-time PCR analysis showed that mRNA levels of *Cnr1*, *Cnr2*, and *Gpr55* (the genes encoding for CB~1~R, CB~2~R, and GPR55, respectively) decreased dramatically during in vivo meiotic maturation, from GV to MI and MII stage ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}A; vs. GV, *p* \< 0.05). Conversely, *Trpv1* (the gene encoding for TRPV1) mRNA expression was very low throughout meiotic maturation, with no significant differences between GV, MI, and MII ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}A; *p* \> 0.05).

2.2. Protein Levels of eCB-Binding Receptors in GV, MI, and MII Oocytes {#sec2dot2-ijms-20-02866}
-----------------------------------------------------------------------

Receptors of eCBs were immunodetected in lysates of in vivo matured oocytes. At GV stage, similar levels of CB~1~R, CB~2~R, and GPR55 proteins were found ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}B; *p* \> 0.05). At MI, CB~1~R content was significantly reduced ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}B; GV vs. MI and MII, *p* \< 0.05), while CB~2~R and even more GPR55 expression levels showed a sharp increase ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}B; GV vs. MI: *p* \< 0.05). As reported in [Figure 1](#ijms-20-02866-f001){ref-type="fig"}B, in MII oocytes only GPR55 content raised dramatically ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}B; GPR55: GV vs. MI vs. MII, *p* \< 0.05; CBR2: MI vs. MII, *p* \> 0.05). TRPV1 signal was always barely detectable at any meiotic stage analyzed ([Figure 1](#ijms-20-02866-f001){ref-type="fig"}A,B; *p* \> 0.05).

2.3. Localization of eCB-Binding Receptors in GV, MI, and MII Oocytes {#sec2dot3-ijms-20-02866}
---------------------------------------------------------------------

In these experiments, the immunolocalization of CB~1~R, CB~2~R, GPR55, and TRPV1 was carried out in oocytes collected in vivo at GV, MI, and MII. At GV stage, all receptors showed a homogeneous distribution over the entire cytoplasm even if CB~1~R immunostaining was more intense than that of CB~2~R and GPR55 ([Figure 2](#ijms-20-02866-f002){ref-type="fig"}A,B). In MI oocytes, while CB~1~R signal intensity was restricted to some cytoplasmic dots, that of CB~2~R and GPR55 increased, being still homogeneously distributed across the germ cell ([Figure 2](#ijms-20-02866-f002){ref-type="fig"}A,B). At MII, fluorescence was very faint for CB~1~R, unchanged for CB~2~R but not for GPR55, as it was remarkably enhanced ([Figure 2](#ijms-20-02866-f002){ref-type="fig"}A,B). In keeping with molecular data, signal intensity of TRPV1 was barely detectable throughout meiotic maturation ([Figure 2](#ijms-20-02866-f002){ref-type="fig"}A,B).

Analysis of CB~1~R localization at oocyte plasma membrane (oolemma) revealed its presence at GV stage, while it failed to detect it at MI and MII stage ([Figure 3](#ijms-20-02866-f003){ref-type="fig"}A). Unlike CB~1~R, the other 3 receptors were never found at oolemma at any meiotic stage analyzed (GV: [Figure 3](#ijms-20-02866-f003){ref-type="fig"}A; MI, MII: data not shown). To further characterize CB~1~R dynamics during the transition from GV to MI, oocytes were collected at 0, 3, 5, and 8 h after human chorionic gonadotropin (hCG). It was found that the homogenous distribution of CB~1~R recorded at 0 h was lost 3 h later, when receptor localization was restricted to small microdomains, probably associated with lipid rafts ([Figure 3](#ijms-20-02866-f003){ref-type="fig"}B). At 5 h, CB~1~R was almost completely compartmentalized in few microdomains, and its signal disappeared from oolemma when oocytes reached the MI stage ([Figure 3](#ijms-20-02866-f003){ref-type="fig"}B).

2.4. Effects of Receptor Antagonists on Intraoocyte cAMP Concentration {#sec2dot4-ijms-20-02866}
----------------------------------------------------------------------

In these experiments, the effects of SR1 and SR2, antagonists of CB~1~R and CB~2~R respectively, on the kinetics of meiotic resumption and cAMP concentration were tested. Antagonists were used alone or in combination at the final concentration of 0.5 µM. As shown in [Figure 4](#ijms-20-02866-f004){ref-type="fig"}A, 30 min after starting culture, almost all oocytes were still arrested at GV stage (Ctr vs. SR1, SR2, SR1+SR2; *p* \> 0.05). At 60 min, germinal vesicle breakdown (GVBD) occurred in about 40% of Ctr oocytes, and in about 20% of oocytes treated with SR1, SR2 or both antagonists ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}A; Ctr vs. SR1, SR2, SR1+SR2; *p* \< 0.05). After 90 min, about 95% of Ctr oocytes underwent GVBD as compared with about 56% of oocytes treated with SR1, SR2 or both antagonists ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}A; Ctr vs. SR1, SR2, SR1+SR2; *p* \< 0.05). At a later time (120 min), almost all oocytes had resumed meiosis (Ctr vs. SR1, SR2, SR1+SR2; *p* \> 0.05). When both antagonists were present, the percentages of oocytes resuming meiosis were similar to those of SR1 or SR2 at any time point tested ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}A; SR1+SR2 vs. Ctr; *p* \> 0.05).

On the basis of the kinetics of meiotic resumption, in the next set of experiments we tested the hypothesis that CB~1~R and CB~2~R, both able to activate G~αi~ proteins \[[@B26-ijms-20-02866]\], could be involved in meiotic resumption by modulating cAMP intraoocyte concentration \[[@B27-ijms-20-02866],[@B28-ijms-20-02866]\]. To this end, cAMP concentration was determined in oocytes cultured in vitro up to 120 min either in the absence (Ctr) or in the presence of SR1, SR2 or SR1+SR2. At the beginning of culture, cAMP content was 0.30 ± 0.01 fmol/oocyte, and 30 min later it showed a slight yet not significant decrease under all experimental conditions ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}B; *p* \> 0.05). A sharp decrease in cAMP concentration occurred at 60 min in SR1-, SR2-, and SR1+SR2-treated cells (\~0.21 ± 0.012 fmol/oocyte) and even more in Ctr (0.16 ± 0.007 fmol/oocyte) ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}B, vs. Ctr; *p* \< 0.05). At 90 min, cAMP concentration was undetectable in Ctr oocytes, while it was \~0.11 ± 0.015 fmol/oocyte in SR1-, SR2-, and SR1+SR2-treated cells ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}B; Ctr vs. SR1, SR2, SR1+SR2, *p* \< 0.05). After 120 min, cAMP was no longer detectable in all groups ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}B; Ctr vs. SR1, SR2, SR1+SR2, *p* \> 0.05). Similar results were obtained in the presence of both antagonists ([Figure 4](#ijms-20-02866-f004){ref-type="fig"}B).

2.5. Effects of Receptor Antagonists on Polar Body I Emission and Spindle Morphology {#sec2dot5-ijms-20-02866}
------------------------------------------------------------------------------------

In these experiments, it was ascertained whether antagonists of CB~1~R, CB~2~R, and GPR55 could affect polar body I (PBI) emission and/or the morphology of MI-MII spindles. The presence of SR1, SR2 or ML193 (0.5 µM) did not perturb in vitro maturation (IVM), as the percentage of oocytes reaching MI (\>90%; vs. Ctr, *p* \> 0.05) and MII stage (\~80% PBI; vs. Ctr, *p* \> 0.05) were comparable with control. Similar results were obtained when oocytes underwent IVM in the presence of the 3 antagonists (MI: \>90%; vs. Ctr, *p* \> 0.05; MII: \~82% PBI; vs. Ctr, *p* \> 0.05) ([Table 1](#ijms-20-02866-t001){ref-type="table"}).

The presence of SR1 or SR2 did not affect normal chromosome alignment at both metaphase plates (\>95%; vs. Ctr, *p* \> 0.05) nor spindle morphology, as more than 80% of oocytes had a mean spindle length (MI: \~35.25 ± 0.19 µm; MII: \~32.39 ± 0.24 µm) and area (MI: \~569.78 ± 3.17 µm^2^; MII: \~481.52 ± 1.64 µm^2^) comparable with Ctr ([Figure 5](#ijms-20-02866-f005){ref-type="fig"}A,B; *p* \> 0.05). Conversely, ML193 dramatically affected overall spindle morphology, but not chromosome alignment, at either MI or MII stage. Indeed, about 75% of MI and MII oocytes cultured in the presence of this GPR55 antagonist displayed spindles significantly shorter (MI: 24.34 ± 0.44 µm; MII: 22.96 ± 0.30 µm) and with smaller areas (MI: 376.44 ± 2.42 µm^2^; MII: 247.60 ± 1.31 µm^2^), as compared with Ctr ([Figure 5](#ijms-20-02866-f005){ref-type="fig"}C--E; *p* \< 0.05).

3. Discussion {#sec3-ijms-20-02866}
=============

Our results demonstrate that (i) the four major eCB-binding receptors are expressed in mouse oocytes, but CB~1~R, CB~2~R, and GPR55 expression changes throughout in vivo meiotic maturation. Conversely, TRPV1 expression is always low/undetectable; (ii) CB~1~R and CB~2~R can play a role in meiotic resumption, while GPR55 could be involved in spindle organization.

We found that *Cnr1*, *Cnr2*, and *Gpr55* mRNAs are expressed in oocytes at GV, while their amounts decrease drastically at MI and MII in keeping with the well-known repression of transcription that follows GVBD \[[@B29-ijms-20-02866]\]. Part of these data are different from those recently reported on CB~2~R mRNA, that was found to be expressed throughout in vivo maturation \[[@B25-ijms-20-02866]\]. This could be due to the different methodology used for MI and MII oocyte recruitment utilized in the two studies. Indeed, we obtained MI by puncturing ovarian follicles 8 h after hCG and MII oocytes from the oviducts 12 h after hCG, while López-Cardona and colleagues retrieved both MI and MII from the oviducts 14 h after hCG \[[@B25-ijms-20-02866]\]. As for humans, only CB~1~R transcripts were reported in mouse oocytes \[[@B21-ijms-20-02866]\], though cells of different meiotic stages were pooled together, thus preventing any conclusion on their modulation during meiosis.

In our experiments, localization of CB~1~R at GV oolemma is modified during GVBD, as CB~1~R is progressively clustered in large microdomains probably associated with lipid-rafts, a preferential localization documented also in neuronal cells \[[@B30-ijms-20-02866]\]. We hypothesized that CB~1~R disappearance from oolemma could be relevant for fertilization and/or early embryo development. It has been demonstrated that in the ampulla, where fertilization occurs, AEA concentration is low, but that spermatozoa here present have undergone CB~1~R-dependent acrosome reaction (AR) in the isthmus, where AEA concentration is high \[[@B12-ijms-20-02866],[@B31-ijms-20-02866]\]. As a consequence, we cannot exclude that the permanence of CB~1~R at the oocyte plasma membrane could trigger inappropriate signalling during the meiotic maturation and fertilization process. Moreover, it is worth to notice that both CB~1~R and CB~2~R are expressed in the early embryo (CB~2~R in the zygote and CB~1~R from 2 cell-embryo stage onward \[[@B32-ijms-20-02866]\]), but with different and still unexplained roles. In fact, while CB~2~R is unresponsive to agonist stimulation and its role has not been yet identified \[[@B25-ijms-20-02866],[@B33-ijms-20-02866]\], CB~1~R plays a key role in embryonic development \[[@B33-ijms-20-02866],[@B34-ijms-20-02866]\]. To date, nothing is yet known about the other receptors.

Our results show that CB~2~R, GPR55, and TRPV1 receptors have different dynamics during meiotic maturation. While TRPV1 is weakly expressed at any meiotic stage, CB~2~R content increases from GV to MI and that of GPR55 throughout the whole meiotic maturation. Our results on CB~1~R and CB~2~R are different from those reported by López-Cardona and colleagues \[[@B25-ijms-20-02866]\], who showed that localization of CB~1~R is differentially influenced by in vivo (periphery of the oocyte from GV to MII) or in vitro maturation (firstly in the cytoplasm at GV, and then peripherally at MII). Such a different distribution is unexpected, since oocytes collected at GV display identical properties regardless of conditions adopted for subsequent (in vivo or in vitro) maturation. Also, for CB~2~R, López-Cardona and colleagues \[[@B25-ijms-20-02866]\] found a homogeneous immunofluorescence in the cytoplasm at all meiotic stages, while we recorded a sharp increase of CB~2~R signal from GV to MI. Although the different procedures used to collect oocytes might explain this discrepancy, the quantification of protein expression performed here strongly supports confocal images.

An additional point of interest is that López-Cardona and colleagues \[[@B25-ijms-20-02866]\] concluded that CB~1~R is more important than CB~2~R in the control of oocyte maturation. Instead, here a role for both receptors in the control of meiotic resumption is supported by experiments with selective receptor antagonists SR1 and SR2. Indeed, the significant delay of GVBD and higher cAMP concentration allow us to conclude that both receptors can modulate oocyte adenylyl cyclase activity, possibly through G~αi~ proteins coupled to them, as shown in other cell systems \[[@B26-ijms-20-02866]\]. It is well known that meiotic arrest in GV oocytes is maintained by a high intra-oocyte cAMP concentration \[[@B27-ijms-20-02866],[@B28-ijms-20-02866]\]. The autonomous production of this cyclic nucleotide is ensured by the presence of active GPR3 receptors coupled to G~αs~ proteins, which maintains the high levels of cAMP necessary for GV arrest via activation of adenylyl cyclase type 3 \[[@B28-ijms-20-02866],[@B35-ijms-20-02866]\]. Following gonadotropin stimulation, cAMP concentration in the oocyte falls down sharply around the time of GVBD, due to gap junction closure and PDE3A activation \[[@B35-ijms-20-02866],[@B36-ijms-20-02866],[@B37-ijms-20-02866]\]. Lowther et al. \[[@B38-ijms-20-02866]\] found that also GPR3 endocytosis through a beta-arrestin/GRK-independent mechanism participates in meiotic resumption. Since we observed that CB~1~R becomes entrapped in large clusters soon after GVBD and disappears from the oolemma at MI, we hypothesize that the concomitant internalization of CB~1~R and GPR3 could be part of the mechanism(s) involved in the control of meiotic resumption. As a matter of fact, receptor endocytosis modulates in the control of GVBD in vertebrate oocytes \[[@B39-ijms-20-02866]\]. The co-existence in GV oocytes of serpentine receptors coupled to G~αi~ proteins, localized either in plasma membranes (CB~1~R) \[[@B26-ijms-20-02866],[@B30-ijms-20-02866]\] or intracellularly (CB~2~R) \[[@B40-ijms-20-02866]\], could be instrumental to properly regulate intra-oocyte cAMP concentration and GVBD \[[@B41-ijms-20-02866]\]. This hypothesis is further corroborated by the presence of functional microdomains for cAMP production in plasma membrane and cytoplasm of many cell types \[[@B42-ijms-20-02866]\], as in fish oocytes \[[@B43-ijms-20-02866]\] and in rat oocyte nucleus \[[@B44-ijms-20-02866]\].

From our experiments it is also evident that the use of SR1 and SR2 during IVM does not induce any variation in meiotic spindle structure and in the percentage of MII oocytes extruding normal PBI. This result is in agreement with the observation by López-Cardona and colleagues \[[@B25-ijms-20-02866]\] on *Cnr1* or *Cnr2* knockout mice, although the presence of both receptors during oocyte growth and maturation is essential for successful fertilization and embryogenesis.

Conversely, a novel role of GPR55 in the formation of MI and MII spindles has been revealed by experiments with its antagonist. In fact, despite nearly all the oocytes cultured with ML193 extrude normal PBI, a high percentage of them exhibits variation in spindle size at both MI (75%) or MII (75%) stage compared with Ctr (19% for MI, 5% for MII), without compromising chromosome alignment at both metaphase plates. To the best of our knowledge, this is the first time that a link between GPR55 and spindle organization has been found in mammalian cells. In mammalian oocytes, spindle length is controlled by a complex interplay of many proteins \[[@B45-ijms-20-02866],[@B46-ijms-20-02866],[@B47-ijms-20-02866]\], and its normal length is considered a marker of oocyte quality \[[@B48-ijms-20-02866]\]. Recently, Wang and collaborators proposed that spindle size and timing of meiotic progression are efficiently controlled more by cytoplasmic than by nuclear components \[[@B49-ijms-20-02866]\]. In keeping with this hypothesis, dynein, dynactin and NuMA are able to control microtubule length, while γ-tubulin regulates the polymerization of α-tubulin \[[@B50-ijms-20-02866]\]. Although we do not know how GPR55 could affect spindle morphology yet, here we show that GPR55 protein is entirely localized in the cytoplasm and its expression raises in a stepwise manner from GV to MI and, more greatly, to MII. This finding supports a possible role for this receptor not only in meiotic maturation but, at later times, also in fertilization and embryo development. It is of interest that GPR55 can mediate Ca^2+^ mobilization from IP3-sensitive intracellular stores via G~q~, G~α12~, RhoA, PLC, and actin \[[@B51-ijms-20-02866]\], and that an essential role for GPR55 activation in the Ca^2+^-dependent regulation of human sperm motility and capacitation has been proposed \[[@B52-ijms-20-02866],[@B53-ijms-20-02866]\]. How GPR55 can participate in the oocyte spindle formation is currently under study in our laboratories. Altogether, these observations suggest that we are still far from understanding the importance of the whole ECS in female reproduction.

4. Materials and Methods {#sec4-ijms-20-02866}
========================

4.1. Chemicals {#sec4dot1-ijms-20-02866}
--------------

Hepes-buffered Eagle's minimal essential medium (MEM-HEPES) and MEM-ALPHA modification (αMEM), penicillin, and streptomycin were purchased from ThermoFisher Scientific (MA, USA). Pregnant mare serum gonadotropin (PMSG, Folligon) and human chorionic gonadotropin (hCG, Corulon) were obtained from Intervet International B. V. (AN Boxmeer, Nederland). SR141716A (SR1; cat. 0923/10) and SR144528 (SR2; cat. 5039/10) were obtained from Tocris Bioscience, Bristol, UK). ML193 trifluoroacetate (ML193, cat. SML1340) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Primary antibodies against rabbit CB~1~R (cat. 101500), CB~2~R (cat. 101550), GPR55 (cat. 10224), and specific blocking peptides for CB~1~R (cat. 301500) and CB~2~R (cat. 301550) and GPR55 (cat. 10225) antibodies were obtained from Cayman Chemical (Anne Arbore, MI, USA). Rabbit TRPV1 (cat. TA336871) antibody was obtained from OriGene Technologies, Inc. (Rockville, MD, USA). Cyanine 3 bisacid (Cy-3) anti-rabbit (cat. A10520) and Alexa Fluor 488 anti-mouse (cat. A32723) used as secondary antibodies for immunofluorescence analysis, and goat anti-rabbit horseradish peroxidase (HRP, cat. 111-035-003), used as secondary antibody for western blotting, were obtained from ThermoFisher Scientific. All the other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), and were of the purest analytical grade.

4.2. Animals {#sec4dot2-ijms-20-02866}
------------

*Mus musculus* Swiss CD1 female mice (23--25 day old; Charles River Laboratories, Lecco, Italy) were housed in an animal facility under controlled temperature (21 ± 1 °C) and light (12 h light/day) conditions, with free access to food and water.

All mice were injected with PMSG (5 IU, i.p.). Forty-two to forty-four hours later, mice were sacrificed to obtain preovulatory germinal vesicle (GV)-stage oocytes or were injected with hCG (5 IU, i.p.) and sacrificed 3--12 h after hCG injection (depending on experimental protocols). MI and MII oocytes were retrieved 8 and 12 h after hCG injection, respectively.

4.3. Ethical Approval {#sec4dot3-ijms-20-02866}
---------------------

All experimental procedures involving animals and their care were performed in conformity with national and international laws and policies (European Economic Community Council Directive 86/609, OJ 358, 1, 12 December, 1987; European Parliament Council Directive 2010/63/EU, OJ L 276, 20 October 2010; Italian Legislative Decree 116/92, Gazzetta Ufficiale della Repubblica Italiana n. 40, 18, February 1992; National Institutes of Health Guide for the Care and Use of Laboratory Animals, NIH publication no. 85-23, 1985). The project was approved by the Italian Ministry of Health and the internal Committee of the University of L'Aquila. The method of euthanasia consisted of an inhalant overdose of carbon dioxide (CO~2~, 10--30%), followed by cervical dislocation. All efforts were made to minimize suffering. A total number of 200 mice were utilized to perform all the experimental procedures.

4.4. Collection of In Vivo Matured Oocytes {#sec4dot4-ijms-20-02866}
------------------------------------------

Fully-grown, GV-stage oocytes surrounded by cumulus cells (oocyte-cumulus cell complexes, OCC) were collected in MEM-HEPES supplemented with 0.23 mM pyruvic acid, 2 mM [l]{.smallcaps}-glutamine and 0.3% BSA (here referred as MEM), and immediately devoid of cumulus cells by gentle pipetting. MI and MII oocytes were recovered from ovaries 8 h after hCG and from fallopian tubes 12 h after hCG, respectively. When needed, cumulus cells were removed by a brief hyaluronidase treatment \[[@B54-ijms-20-02866]\]. Oocytes were immediately used for morphological or molecular analysis.

4.5. Quantitative Real-Time PCR Analysis {#sec4dot5-ijms-20-02866}
----------------------------------------

Total RNA was extracted from GV, MI and MII oocytes (20 oocytes/sample) using the RNeasy extraction kit (Qiagen, Crawley, UK) as suggested by the manufacturer. Starting with 100 ng of RNA, complementary DNA (cDNA) was prepared using M--MLV reverse transcriptase kit (ThermoFisher Scientific, Waltham, MA, USA). Quantitative PCR analysis was performed using SYBR Green I Master and the LightCycler 480 System (Roche, Basel, Switzerland) on a DNA Engine Opticon 2 Continuous Fluorescence Detection System (BioRad, Hercules, CA, USA). The reaction was performed using the following qRT-PCR program: 95 °C for 10 min, followed by 40 amplification cycles of 95 °C for 10 s, 57 °C for 30 s, and 72 °C for 30 s. The primer used for the amplification of *Cnr1*, *Cnr2*, *Gpr55*, and *Trpv1* \[[@B55-ijms-20-02866],[@B56-ijms-20-02866]\] were listed in [Table 2](#ijms-20-02866-t002){ref-type="table"} and all the data were normalized to the endogenous reference gene β-Actin. Relative quantitation of mRNAs was performed by the comparative ΔΔ*C*t method \[[@B57-ijms-20-02866]\].

4.6. Western Blotting Analysis {#sec4dot6-ijms-20-02866}
------------------------------

GV, MI, and MII oocytes (150 oocytes/sample) were lysed in sample buffer containing protease inhibitors (2 mM phenylmethyl sulphonyl fluoride, 10 µg/mL aprotinin, 0.1 mM sodium pyrophosphate, 10 mM sodium fluoride, and 1 mM sodium orthovanadate). Lysates were separated by electrophoresis and transferred to nitrocellulose membranes (Hybond C Extra, Amersham, UK). Membranes were incubated with antibodies against CB~1~R (1:200), CB~2~R (1:200), GPR55 (1:200), and TRPV1 (1:200) overnight at 4 °C. HRP-conjugated goat anti-rabbit IgG (1:5000) was used as secondary antibody (1 h, room temperature); peroxidase activity was detected using a SuperSignal West Pico Chemiluminescent substrate. Membranes were examined by Alliance LD2-77WL imaging system (Uvitec, Cambridge, UK). Densitometric quantification was performed with the public-domain software NIH Image 167 V.1.62 and standardized using tubulin as loading control. Negative controls were prepared using specific blocking peptide (for CB~1~R and CB~2~R and GPR55). For the anti-TRPV1 antibody used in this study, there are no blocking peptides commercially available.

4.7. Immunofluorescence {#sec4dot7-ijms-20-02866}
-----------------------

To detect presence and distribution of receptors at GV, MI and MII stage, oocytes (15/sample) were fixed in 4% paraformaldehyde for 10 min at r.t., permeabilized with 0.1% Triton X-100 for 30 min at 37 °C \[[@B54-ijms-20-02866],[@B58-ijms-20-02866]\]. Afterwards, oocytes were incubated with the following primary antibodies diluted in a PBS blocking solution (containing 2% BSA, 2% powder milk, 2% normal goat serum, 0.1 M Glycine, and 0.01% Triton X-100): CB~1~R (1:100), CB~2~R (1:100), GPR55 (1:200), and TRPV1 (1:200) for 1 h at 37 °C. To detect receptor presence at oocyte plasma membrane (oolemma), oocytes were firstly incubated in Tyrode's solution at pH 2.5 to remove zona pellucida (zona-free, ZF), and then fixed in 4% paraformaldehyde (0.2% BSA in 0.1 M PBS pH 7.4). Afterwards, oocytes were incubated for 1 h at 37 °C with the following primary antibodies diluted in 0.2% BSA-PBS: CB~1~R (1:100), CB~2~R (1:100), GPR55 (1:200), and TRPV1 (1:200). Oocytes were then incubated with Cy-3 anti-rabbit secondary antibody (1:200) for 1 h at 37 °C, mounted using 1.5 µl of 50% glycerol/PBS solution containing sodium azide and DAPI (1:1000) to label nuclei \[[@B59-ijms-20-02866]\]. To monitor the distribution of CB~1~R in the oolemma during the GV--MI transition, ZF-oocytes were collected at different times after hCG injection (0, 3, 5, 8 h; 15 oocytes/time point), and incubated with CB~1~R antibody (1:100)-Cy-3 anti-rabbit secondary antibody (1:200) for 1 h at 37 °C each.

For each set of experiments, negative controls (NC) were prepared using specific blocking peptide (for CB~1~R and CB~2~R and GPR55) and omitting the primary antibody for TRPV1 before addition of the secondary antibody. For the anti-TRPV1 antibody used in this study there are no blocking peptides commercially available. All the oocytes were observed by confocal microscopy (Leica System TCS SP5 confocal microscope, Wetzlar, Germany). Images were taken at the equatorial plan using the LAS AF software (Leica Microsystems).

For image analysis, data from high-resolution images of 6 oocytes from 3 independent experiments were acquired for each sample. Quantification of the intracellular mean fluorescence of CBRs was carried out using the public-domain software NIH Image 167 V.1.62 after the subtraction of the background intensity calculated from the images of NC.

4.8. Effects of CB~1~R and CB~2~R Antagonists on Intraoocyte cAMP Content {#sec4dot8-ijms-20-02866}
-------------------------------------------------------------------------

OCCs were collected in MEM supplemented with cilostamide (1 µM) to maintain meiotic arrest \[[@B60-ijms-20-02866]\]. After washing, OCCs were (i) in part devoid of somatic cells to obtain GV stage oocytes (*t* = 0) that were immediately stored at −80 °C; (ii) in part cultured at 37 °C in 5% CO~2~ for 30, 60, 90, and 120 min in the absence (Ctr) or presence of CB~1~R antagonist SR141716 (SR1) and CB~2~R antagonist SR244528 (SR2), alone or in combination. The antagonists were all used at 0.5 µM because it was the lowest effective dose after preliminary experiments, and for CB~1~R and CB~2~R was in line with previous study \[[@B57-ijms-20-02866]\]. Culture medium was alpha MEM supplemented with 0.23 mM pyruvate, 2 mM [l]{.smallcaps}-glutamine and 0.05% DMSO (hereafter referred as αMEM-DMSO). At each time point, OCCs were deprived of cumulus cells to record the percentage of GVs, according to the presence or absence of the GV in the ooplasm.

The amount of cAMP was determined in groups of 120 oocytes incubated stored after GV assessment, by using a Cyclic AMP EIA Kit (581001, Cayman Chemical Company, Anne Arbore, MI, USA) according to manufacturer's instructions. Absorbance at 420 nm was measured in a Model 550 microplate reader (BioRad).

4.9. Effects of Receptor Antagonists on Polar Body I Emission and Spindle Formation {#sec4dot9-ijms-20-02866}
-----------------------------------------------------------------------------------

To evaluate the effects of antagonists on the morphology of MI spindle, OCCs were cultured for 8 h in 300 μL αMEM-DMSO in the absence (Ctr, *n* = 30 oocytes) or presence of 0.5 µM SR1 (*n* = 45 oocytes), SR2 (*n* = 45 oocytes), ML193 (*n* = 80 oocytes), or a combination of the three antagonists (SR1 + SR2 + ML193; *n* = 50 oocytes). Following cumulus cells removal, only oocytes undergoing GVBD were fixed as described in the following procedure.

The analysis of antagonists' effect on PBI and MII spindles were performed by retrieving OCCs 8h after hCG, i.e., at MI in vivo, and then by culturing them in the absence (Ctr, *n* = 30 oocytes) or presence of 0.5 µM SR1 (*n* = 30 oocytes), SR2 (*n* = 50 oocytes) or ML193 (*n* = 80 oocytes), or a combination of the three antagonists (SR1+SR2+ML193; *n* = 50 oocytes) for 5 h. This experimental design was chosen in order to reduce the times of oocyte in vitro culture. By the end of culture period, the percentage of normal PBI was recorded, and oocytes were then fixed as described above. Afterwards, oocytes were incubated for 1 h at 37 °C with anti-tubulin primary antibody (1:100) and then with anti-mouse secondary antibody conjugated with Alexa Fluor 488 (1:1000). Chromosomes were labelled with DAPI (1:1000) \[[@B58-ijms-20-02866],[@B59-ijms-20-02866]\]. Spindle sizes (length \[[@B49-ijms-20-02866]\] and area \[[@B61-ijms-20-02866]\]) were measured by the software ZEN 2009 Light Edition (Carl Zeiss MicroImaging GmbH), as previously described \[[@B49-ijms-20-02866]\].

4.10. Statistical Analyses {#sec4dot10-ijms-20-02866}
--------------------------

All experiments were performed at least 3 times, and data obtained were expressed as the mean ± S.E.M. Statistical analysis was performed using ANOVA followed by the Tukey-Kramer post-test for comparison of multiple groups, by Bonferroni post-test for comparison among treatments and control groups and by the chi-square test for comparison of percentages. Values of *p* \< 0.05 were considered significantly different.

5. Conclusions {#sec5-ijms-20-02866}
==============

Our results demonstrate that in mouse oocytes the major eCB-binding receptors are differentially expressed and modulated during meiotic maturation. Present data support a prominent role for CB~1~R and CB~2~R in the control of meiosis resumption, and the engagement of GPR55 in MI and MII spindle organization. These findings open a new avenue to interrogate oocyte pathophysiology and offer potentially novel biomarkers for fertility problems.

The authors thank Mariangela Pucci (University of Teramo), Valeria Gasperi (Tor Vergata, University of Rome), Annalisa Castellucci and Alessio Ferrari (University of L'Aquila) for their kind help in the preliminary steps of this project.

Conceptualization, S.C. and M.M.; Data curation, S.C.; Funding acquisition, S.C. and M.M.; Methodology, G.R., S.O. and V.D.N.; Supervision, S.C., S.O. and M.M.; Writing---original draft, S.C., V.D.N., G.R., S.O. and M.M.; Writing---review & editing, S.C., G.R., V.D.N. and M.M.

This work was supported by grants from the University of L'Aquila to S.C. (RIA 2016-17).

The authors declare no conflict of interest.

2-AG

2-arachidonoylglycerol

AEA

N

-arachidonoylethanolamine

AU

Arbitrary units

BSA

Bovine Serum Albumin

cAMP

Cyclic adenosine monophosphate

CB

1

R

Cannabinoid receptor type-1

CB

2

R

Cannabinoid receptor type-2

CTR

Control

Cy-3

Cyanine 3 bisacid

DAPI

4′,6-diamidino-2-phenylindole

DMSO

Dimethyl sulfoxide

eCBs

Endocannabinoids

ECS

Endocannabinoid system

ERK 1/2

Extracellular signal-regulated kinases 1/2

FAAH

Fatty acid amide hydrolase

GCs

Granulosa cells

GPR3

G protein-coupled receptor 3

GPR55

G-protein coupled receptor 55

GRK

G protein-coupled receptor kinase

GV

Germinal vesicle

GVBD

Germinal vesicle breakdown

hCG

Human chorionic gonadotropin

HU-210

1,1-Dimethylheptyl-11-hydroxy-tetrahydrocannabinol

IP3

Inositol trisphosphate

IVM

In vitro maturation

MI

Metaphase I

MII

Metaphase II

ML193

N

-\[4-\[\[(3,4-dimethyl-5-isoxazolyl)amino\]sulfonyl\]phenyl\]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide

NAPE-PLD

N

-acyl phosphatidylethanolamine-specific phospholipase D

NC

Negative control

NuMA

Nuclear mitotic apparatus protein 1

OCCs

Oocyte-cumulus complexes

OEA

N

-oleoylethanolamine

OSE

Ovarian surface epithelium

PBI

Polar body I

PCOS

Polycystic ovary syndrome

PDE3A

Phosphodiesterase 3A

PEA

N

-palmitoylethanolamine

PLC

Phospholipase C

PMSG

Pregnant mare serum gonadotropin

RhoA

Ras homolog gene family, member A

SR1

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide hydrochloride

SR2

5-(4-Chloro-3-methylphenyl)-1-(4-methylbenzyl)-

N

-((1S,2S,4R)-1,3,3-trimethylbicyclo\[2.2.1\]heptan-2-yl)-1H-pyrazole-3-carboxamide

TRPV1

Transient receptor potential vanilloid type 1 channel

ZF

Zona-free

![Expression levels of endocannabinoids (eCBs)-binding receptors during mouse oocyte in vivo meiotic maturation. (**A**) Real-time PCR of *Cnr1*, *Cnr2*, *Gpr55*, and *Trpv1*. Data were reported as 2^−ΔΔ*C*t^ values calculated by Delta--Delta Ct (ΔΔ*C*t) method vs. germinal vesicle (GV) (*Cnr1*) group posed equal to 1. Expression was normalized to *Actb* and values were reported as mean ± SEM of 4 independent replicates. \* *p* \< 0.05 vs. GV oocyte of the same experimental group. (**B**) Representative western blot and quantification of cannabinoid receptor type-1 and -2 (CB~1~R and CB~2~R), G-protein coupled receptor 55 (GPR55), and transient receptor potential vanilloid type 1 channel (TRPV1) protein contents. Data are expressed as mean ± SEM of each receptor content after normalization with α/β-tubulin, used as loading control. Experiments were repeated 3 times. \* *p* \< 0.05 vs. GV oocyte of the same experimental group; \*\* *p* \< 0.05 vs. MI of the same experimental group. GV = germinal vesicle; MI = metaphase I; MII = metaphase II.](ijms-20-02866-g001){#ijms-20-02866-f001}

![(**A**) Localization of CB~1~R, CB~2~R, GPR55, and TRPV1 receptors in mouse oocytes collected at various stages of in vivo meiotic maturation. Receptors were labelled with Cy-3 (red), DNA was counterstained by DAPI (cyan). In the upper right-hand corner of GV CB~1~R, the strong DAPI staining is due to undetached cumulus cell nuclei. Each image was taken at the equatorial plan of the oocyte. Magnification: ×630. Each inset represents a magnified part of ooplasm. GV = germinal vesicle; MI = metaphase I; MII = metaphase II; NC = negative control. (**B**) Mean fluorescence of CB~1~R, CB~2~R, GPR55, and TRPV1 receptors in mouse oocytes collected at different stages of meiotic maturation. Values are expressed as arbitrary units (AU) and are reported as mean ± SEM of 6 oocytes from 3 independent experiments. \* *p* \< 0.05 vs. GV oocyte of the same experimental group; \*\* *p* \< 0.05 vs. MI of the same experimental group.](ijms-20-02866-g002){#ijms-20-02866-f002}

![Distribution of CB~1~R, CB~2~R, GPR55, and TRPV1 in the oolemma and CB~1~R localization at oolemma during in vivo GV--MI transition. (**A**) Only GV oocytes showed detectable signals. Qualitative data are expressed as presence (+) or absence (-) of fluorescence in 15 oocytes/sample. (**B**) CB~1~R distribution, analyzed at different times after human chorionic gonadotropin (hCG), changed from uniformly homogeneous (0--3 h) to dotted clusters (5 h), until complete disappearance at MI (8 h). Each image was taken at the equatorial plan of the oocyte. Cy-3: red, DAPI: cyan. Magnification: ×630.](ijms-20-02866-g003){#ijms-20-02866-f003}

![Effects of CBRs antagonists on the kinetics of oocyte germinal vesicle breakdown (GVBD) and on cAMP concentration. (**A**) Oocyte--cumulus cell complexes (OCCs) were matured in vitro in the presence of 0.05% DMSO (Ctr) or SR1, SR2, and SR1 + SR2 (0.5 μM) for 30, 60, 90, and 120 min. Data are expressed as percentage of GV arrested/total oocytes. *nd*: not detectable (**B**) cAMP concentration (fmol/oocyte) was assayed in oocytes cultured in vitro for 30, 60, 90, and 120 min as Ctr or in the presence of SR1, SR2, and SR1 + SR2 (0.5 μM). Data are expressed as mean ± SEM of 4 independent experiments. \* *p* \< 0.05 vs. Ctr oocytes of the same experimental group. *nd*: values below the limit of detection of the assay (0.1 pmol/mL).](ijms-20-02866-g004){#ijms-20-02866-f004}

![MI and MII spindle morphology and size. To obtain MI oocytes, OCCs were cultured in presence or absence (Ctr) of SR1, SR2, and ML193 (0.5 μM) for 8 h. To obtain MII oocytes, OCCs were collected 8 h after hCG and cultured in vitro for 5 h. Spindles were stained with anti-α/β-tubulin antibody (green) and chromosomes with DAPI (cyan). Representative images of normal MI (**A**) and MII (**B**) spindles and of altered MI (**C**) and MII (**D**) spindles. Magnification: ×630. (**E**) Oocytes percentages of MI and MII altered spindles in presence of CBRs antagonists. Data are expressed as mean ± SEM of 3 independent experiments. \* *p* \< 0.05 vs. Ctr oocytes of the same experimental group.](ijms-20-02866-g005){#ijms-20-02866-f005}

ijms-20-02866-t001_Table 1

###### 

Percentages of oocytes at MI or MII stage after in vitro maturation (IVM) in the presence or absence (Ctr) of CBRs antagonists.

  Condition       Num. of Oocytes   MI (%)         MII (%)
  --------------- ----------------- -------------- --------------
  Ctr             30                96.02 ± 3.98   81.25 ± 2.13
  SR1             45                95.80 ± 3.15   82.93 ± 1.42
  SR2             45                94.56 ± 5.03   80.95 ± 3.26
  ML193           80                95.51 ± 4.36   81.16 ± 2.70
  SR1+SR2+ML193   50                94.83 ± 2.91   81.60 ± 2.24

Note: For complete and detailed information on the different IVM procedures see [Section 4.9](#sec4dot9-ijms-20-02866){ref-type="sec"} Materials and Methods. All oocytes were analyzed by confocal microscopy for the evaluation of spindle morphology.

ijms-20-02866-t002_Table 2

###### 

List of the primers used for quantitative real-time PCR analysis.

  ------------------------------------------------------------------------------------------------------------------
  Gene      Corresponding Protein   PCR Primers                        Annealing T (°C)   Reference
  --------- ----------------------- ---------------------------------- ------------------ --------------------------
  *Cnr1*    CB~1~R                  Fw: 5′-CCAAGAAAAGATGACGGCAG-3′\    57                 \[[@B55-ijms-20-02866]\]
                                    Rev: 5′-AGGATGACACATAGCACCAG-3′                       

  *Cnr2*    CB~2~R                  Fw: 5′-TCGCTTACATCCTTCAGACAG-3′\   57                 \[[@B55-ijms-20-02866]\]
                                    Rev: 5′-TCTTCCCTCCCAACTCCTTC-3′                       

  *Gpr55*   GPR55                   Fw: 5′-ATTCGATTCCGTGGATAAGC-3′\    57                 \[[@B56-ijms-20-02866]\]
                                    Rev: 5′-ATGCTGATGAAGTAGAGGC-3′                        

  *Trpv1*   TRPV1                   Fw: 5′-TGAACTGGACTACCTGGAAC-3′\    57                 \[[@B56-ijms-20-02866]\]
                                    Rev: 5′-TCCTTGAAGACCTCAGCATC-3′                       

  *Actb*    Actin                   Fw: 5′-CTGTCGAGTCGCGTCCACCC-3′\    57                 \[[@B55-ijms-20-02866]\]
                                    Rev: 5′-GCTTTGCACATGCCGGAGCC-3′                       
  ------------------------------------------------------------------------------------------------------------------
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